

## ASX Announcement

### Imugene's HER-Vaxx & CF33 platforms to be featured at ASCO Gastrointestinal Cancers Symposium

---

**Sydney, Australia, 16 December 2022:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that its HER-Vaxx and CF33 technologies will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023.

The 20<sup>th</sup> annual international event highlights the latest developments and breakthroughs in the field of gastrointestinal oncology, attended by more than 4,000 scientific figures, clinical researchers, academics, oncologists and medical practitioners from around the world.

The abstract titles have been announced for the symposium, with Imugene to feature in the following:

#### Oral Abstract Session

- HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis.

<https://meetings.asco.org/abstracts-presentations/215800>

#### Trials in Progress Poster Session

- nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

<https://meetings.asco.org/abstracts-presentations/217557>

#### Poster Session

- Development of a novel chimeric oncolytic viral platform, CF33 and its derivatives, for peritoneal-directed CF33-OV treatment of gastric cancer peritoneal carcinomatosis.

<https://meetings.asco.org/abstracts-presentations/216231>



- Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from patients with gastric cancer with and without peritoneal metastases.

<https://meetings.asco.org/abstracts-presentations/216236>

For more information please contact:

**Leslie Chong**

**Managing Director and Chief Executive Officer**

info@imugene.com

**Investor Enquiries**

investor@imugene.com

**Media Enquiries**

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

View us on YouTube @Imugene Limited

**About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-



oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*

*Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*